Phase 2 Multiple Sclerosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS), confirmed using standard MS diagnostic guidelines
- Your level of physical disability, measured by a standard MS scale, falls within a mild-to-moderate range (a score between 0 and 6.5 out of 10) at the time of your screening appointment
Who may not be able to join:
- You received a specific type of MS treatment called an "anti-CD20" therapy (such as ocrelizumab) less than 2 years ago
- You received an anti-CD20 therapy more than 2 years ago, but your B-cell levels (a type of immune cell) are still lower than normal, or you stopped that treatment because of safety concerns
- You have a history of a serious brain infection called progressive multifocal leukoencephalopathy (PML), either confirmed or suspected (confirm with trial site)
- You have had any form of cancer, including blood cancers or solid tumours, within the past 10 years
- Your immune system is significantly weakened for any reason
- You have had a previous allergic reaction to ocrelizumab or any of its ingredients
- You have had a severe allergic reaction (including anaphylaxis) to similar types of antibody-based medicines in the past
- You have another condition that requires ongoing treatment with steroid or immune-suppressing medicines
- You have a serious, uncontrolled condition affecting your heart, lungs, kidneys, liver, hormone system, or digestive system, or any other significant health condition
- You do not have a usable vein for receiving intravenous (IV) treatment
- You have previously been treated with cladribine, atacicept, or alemtuzumab (specific MS or immune-related medicines)
- You have previously had a bone marrow or stem cell transplant
- You have any history of organ transplantation or have taken anti-rejection medication
- Your screening blood tests show a current or past hepatitis B infection that has not been fully treated
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trials, Hoffmann-La Roche
Phone: 888-662-6728 (U.S.)
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Area Under the Serum Concentration-time Curve Over the First 12 Weeks Post-dose (AUC0-12W) of Ocrelizumab; Maximum Serum Concentration (Cmax) of Ocrelizumab
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.